Universal CAR-T Cells Targeting AML
NCT05995041
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Acute Myeloid Leukemia
Interventions
BIOLOGICAL:
CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells
Sponsor
Shenzhen Geno-Immune Medical Institute